14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $12.37 $15.43 Wednesday, 1st May 2024 URGN stock ended at $14.40. This is 4.20% more than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 5.47% from a day low at $13.89 to a day high of $14.65.
90 days $12.37 $19.87
52 weeks $8.69 $24.13

Historical UroGen Pharma Ltd prices

Date Open High Low Close Volume
Mar 28, 2023 $8.11 $8.37 $7.79 $8.01 180 721
Mar 27, 2023 $8.39 $8.69 $8.12 $8.18 187 656
Mar 24, 2023 $8.29 $8.55 $8.05 $8.39 46 137
Mar 23, 2023 $8.15 $8.60 $7.99 $8.36 70 868
Mar 22, 2023 $8.83 $9.02 $7.75 $8.17 184 619
Mar 21, 2023 $8.51 $9.22 $8.51 $8.75 135 005
Mar 20, 2023 $8.56 $8.81 $8.41 $8.50 80 205
Mar 17, 2023 $9.18 $9.20 $8.37 $8.50 224 924
Mar 16, 2023 $9.79 $9.80 $9.19 $9.33 123 346
Mar 15, 2023 $9.91 $9.91 $9.41 $9.63 42 115
Mar 14, 2023 $9.54 $10.12 $9.28 $10.02 114 675
Mar 13, 2023 $9.61 $9.77 $9.27 $9.45 84 534
Mar 10, 2023 $10.11 $10.30 $9.27 $9.32 147 431
Mar 09, 2023 $10.43 $10.77 $10.11 $10.16 70 123
Mar 08, 2023 $10.36 $10.54 $10.06 $10.43 79 405
Mar 07, 2023 $10.24 $10.63 $9.81 $10.21 60 578
Mar 06, 2023 $10.39 $10.39 $9.72 $10.12 46 050
Mar 03, 2023 $10.51 $10.51 $10.05 $10.30 48 108
Mar 02, 2023 $10.62 $10.64 $10.31 $10.34 36 573
Mar 01, 2023 $10.36 $10.79 $10.29 $10.60 79 729
Feb 28, 2023 $10.20 $10.49 $10.07 $10.30 35 671
Feb 27, 2023 $9.78 $10.37 $9.78 $10.13 88 335
Feb 24, 2023 $10.42 $10.61 $9.67 $9.69 55 894
Feb 23, 2023 $9.94 $10.78 $9.83 $10.40 191 342
Feb 22, 2023 $9.49 $10.35 $9.44 $9.88 54 550
Click to get the best stock tips daily for free!

About UroGen Pharma Ltd

UroGen Pharma Ltd UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms... URGN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT